Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss
Completed · Phase 2
Conditions studied: Cancer Cachexia
In brief
Anorexia and weight loss are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated to stimulate appetite. RC-1291 HCl, by virtue of its ghrelin like activity and Growth Hormone releasing effects may have a dual role in the reversal of cancer induced anorexia and weight loss. This study will test the safety and efficacy of RC-1291 in the treatment of cancer patients with anorexia and weight loss.
Key facts
- Study ID
- NCT00219817
- Run by
- Helsinn Therapeutics (U.S.), Inc
- People needed
- 80
- Starts
- 2005-06-01
- Expected to finish
- 2006-10-01
- Last updated by the study team
- 2013-09-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Community-dwelling patients ≥ 18 years of age with incurable, histologically diagnosed cancer.
- Involuntary loss of body weight of ≥ 5 % within the past 6 months
You may not qualify if…
- Presently hospitalized or in a nursing care facility.
- Inability to increase food intake from secondary causes.
- Liver disease
- If female-pregnant, breast-feeding or of childbearing potential.
Where it is running
- California Cancer Care Center — Greenbrae, California, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Columbia University Medical Center — New York, New York, United States
- University of Texas Medical Branch at Galveston — Galveston, Texas, United States
- Michael E. DeBakey Veterans Affairs Medical Center — Houston, Texas, United States
- Fletcher Allen Health Care — Burlington, Vermont, United States
- Cancer Outreach Associates — Abingdon, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.